Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study

NCT04201769 is registered in ClinicalTrials.gov with Consorzio Oncotech as lead sponsor.

NCT NCT04201769
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04201769 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Standard Regimen of Dexamethasone in Comparison to Two Dex-sparing Regimens in Addition to NEPA in Preventing CINV in naïve NSCLC Patients to be Treated With Cisplatin Based Chemotherapy: a Three-arm, Open-label, Randomized Study
Lead sponsor
Consorzio Oncotech
Phase
Phase 3
Overall status
Unknown status
Start date
November 25, 2016
Completion date
April 30, 2020
Enrollment
261 (actual)
Sites
26

Conditions

As the registry lists them; a condition with its own page is linked.

chemotherapy-induced nausea and vomiting